p27kip1 Expression Distinguishes Papillary Hyperplasia in Graves' Disease from Papillary Thyroid Carcinoma
- 1 September 2000
- journal article
- Published by Elsevier in Laboratory Investigation
- Vol. 13 (9) , 1014-1019
- https://doi.org/10.1038/modpathol.3880182
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cellsJournal of Clinical Investigation, 1999
- Immunohistochemical staining of DNA topoisomerase IIα in human gliomasJournal of Neurosurgery, 1999
- Immunohistochemical detection of DNA topoisomerase type II α and Ki‐67 in adenoid cystic carcinoma and pleomorphic adenoma of the salivary glandJournal of Oral Pathology & Medicine, 1999
- Parathyroid Hyperplasia, Adenomas, and CarcinomasThe American Journal of Surgical Pathology, 1999
- p27kip1: A Multifunctional Cyclin-Dependent Kinase Inhibitor with Prognostic Significance in Human CancersThe American Journal of Pathology, 1999
- Inhibitors of mammalian G1 cyclin-dependent kinases.Genes & Development, 1995
- G1 control in mammalian cellsJournal of Cell Science, 1994
- The Role of Thyroid-Stimulating Antibodies of Graves' Disease in Differentiated Thyroid CancerNew England Journal of Medicine, 1988
- THE SPECTRUM OF THYROID DISEASE IN A COMMUNITY: THE WHICKHAM SURVEYClinical Endocrinology, 1977
- Incidence of thyroid carcinoma in Graves' diseaseCancer, 1970